Orum Therapeutics, Inc. (KOSDAQ:475830)
South Korea flag South Korea · Delayed Price · Currency is KRW
23,100
0.00 (0.00%)
Aug 8, 2025, 3:30 PM KST

Orum Therapeutics Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22
20,89320,906135,41875.92
Revenue Growth (YoY)
-84.57%-84.56%178270.49%-
Cost of Revenue
1.521.99-0.83
Gross Profit
20,89220,904135,41875.09
Selling, General & Admin
9,7239,15819,0549,083
Research & Development
19,17317,04318,70633,168
Other Operating Expenses
157.72170.3280.11182.18
Operating Expenses
32,10629,23939,81143,723
Operating Income
-11,215-8,33595,607-43,648
Interest Expense
-1,840-1,794-824.35-75.37
Interest & Investment Income
2,5733,179560.83671
Currency Exchange Gain (Loss)
-3,076-4,609-5,642-799.86
Other Non Operating Income (Expenses)
429.535,445-21,199-19,197
EBT Excluding Unusual Items
-13,129-6,11468,502-63,050
Gain (Loss) on Sale of Investments
1,343799.27-809.55-52.63
Gain (Loss) on Sale of Assets
--205.258.91
Pretax Income
-11,786-5,31567,898-63,093
Income Tax Expense
425.36424.98-319.02225.34
Net Income
-12,211-5,74068,217-63,319
Net Income to Common
-12,211-5,74068,217-63,319
Shares Outstanding (Basic)
171455
Shares Outstanding (Diluted)
1718155
Shares Change (YoY)
15.33%20.20%227.30%-
EPS (Basic)
-703.14-423.6214829.83-13764.93
EPS (Diluted)
-952.24-555.935646.14-13764.93
Free Cash Flow
-13,717-12,54593,117-41,888
Free Cash Flow Per Share
-789.84-693.226184.75-9106.02
Gross Margin
99.99%99.99%100.00%98.91%
Operating Margin
-53.68%-39.87%70.60%-57492.65%
Profit Margin
-58.45%-27.46%50.38%-83402.60%
Free Cash Flow Margin
-65.65%-60.01%68.76%-55173.99%
EBITDA
-8,163-5,46797,377-42,358
EBITDA Margin
-39.07%-26.15%71.91%-
D&A For EBITDA
3,0522,8681,7711,290
EBIT
-11,215-8,33595,607-43,648
EBIT Margin
-53.68%-39.87%70.60%-
Advertising Expenses
-4.373.9510.28
Source: S&P Global Market Intelligence. Standard template. Financial Sources.